The role of cancer stem cells and the therapeutic potential of TRX-E-002-1 in ovarian cancer

Jessica Illuzzi, Peter Schwartz, Ayesha B. Alvero, Dan-Arin Silasi, Han-Hsuan Fu, Masoud Azodi, Michael Kelly, Gil Mor, Thomas Rutherford, Rui Chen, MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. Yale Journal of Biology and Medicine. ,vol. 79, pp. 153- 163 ,(2006)

Partridge Ee, Clarke-Pearson Dl, Hoskins Wj, Brady Mf, Kucera Pr, Davidson M, Look Ky, McGuire Wp, Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Seminars in Oncology. ,vol. 23, pp. 40- 47 ,(1996)

Alan Husband, Andreas I. Constantinou, Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Research. ,vol. 22, pp. 2581- 2585 ,(2002)

Johanna C. Bendell, Manish R. Patel, Jeffrey R. Infante, Carla D. Kurkjian, Suzanne F. Jones, Shubham Pant, Howard A. Burris, Ofir Moreno, Vanessa Esquibel, Wendy Levin, Kathleen N. Moore, Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors Cancer. ,vol. 121, pp. 1056- 1063 ,(2015) , 10.1002/CNCR.29155

Tiyasha H. Ayub, Mignon-Denise Keyver-Paik, Manuel Debald, Babak Rostamzadeh, Thore Thiesler, Lars Schröder, Winfried Barchet, Alina Abramian, Christina Kaiser, Glen Kristiansen, Walther Kuhn, Kirsten Kübler, Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer Oncotarget. ,vol. 6, pp. 16437- 16448 ,(2015) , 10.18632/ONCOTARGET.4103

David M Robertson, Screening for the early detection of ovarian cancer Women's Health. ,vol. 5, pp. 347- 349 ,(2009) , 10.2217/WHE.09.27

Michael G. Kelly, Gil Mor, Alan Husband, David M. O'Malley, Lisa Baker, Masoud Azodi, Peter E. Schwartz, Thomas J. Rutherford, Phase II Evaluation of Phenoxodiol in Combination With Cisplatin or Paclitaxel in Women With Platinum/Taxane-Refractory/Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers International Journal of Gynecological Cancer. ,vol. 21, pp. 633- 639 ,(2011) , 10.1097/IGC.0B013E3182126F05

Paul L. de Souza, Winston Liauw, Matthew Links, Saiyini Pirabhahar, Graham Kelly, Laurence G. Howes, Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol), a novel isoflav-3-ene, in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. ,vol. 58, pp. 427- 433 ,(2006) , 10.1007/S00280-006-0189-6

Dan-Arin Silasi, Ayesha B Alvero, Thomas J Rutherford, David Brown, Gil Mor, Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert Opinion on Pharmacotherapy. ,vol. 10, pp. 1059- 1067 ,(2009) , 10.1517/14656560902837980

Jane E. Visvader, Geoffrey J. Lindeman, Cancer stem cells in solid tumours: accumulating evidence and unresolved questions Nature Reviews Cancer. ,vol. 8, pp. 755- 768 ,(2008) , 10.1038/NRC2499